Literature DB >> 1640864

Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol.

T Yamanouchi1, H Moromizato, T Shinohara, S Minoda, H Miyashita, I Akaoka.   

Abstract

We investigated the effect of plasma glucose fluctuation on hemoglobin A1c (HbA1c) and plasma 1,5-anhydroglucitol (AG) levels, especially in insulin-dependent diabetes mellitus (IDDM). Plasma AG is a new marker that provides sensitive and analytical information on glycemic control. The basic mechanisms underlying both the reduction and recovery of the plasma AG level, ie, the excretion into urine with glucosuria and the amount supplied to the body, were presumed to be similar in IDDM and non-insulin-dependent diabetes mellitus (NIDDM) patients. The correlation coefficient for mean plasma glucose and AG was -.591, and it was .578 for mean plasma glucose and HbA1c in IDDM patients. In NIDDM, the correlation between mean plasma glucose and AG was -.869, and between mean plasma glucose and HbA1c, .875. The plasma AG levels in the IDDM group showed a lower range than in the NIDDM group, even with similar HbA1c levels. All the cases showing lower plasma AG levels among those with similar HbA1c levels manifested greater fluctuation of plasma glucose and a larger amount of urinary glucose. The lower AG level in IDDM patients was reversible to the level in NIDDM patients when the greater fluctuation of plasma glucose was corrected. Thus, it was suggested that because urinary glucose excretion is intermittently high in IDDM patients, plasma AG is frequently low, even though the mean plasma glucose and HbA1c levels suggest good control.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1640864     DOI: 10.1016/0026-0495(92)90168-a

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  16 in total

Review 1.  Glycated haemoglobin in the year 2000.

Authors:  E S Kilpatrick
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

2.  Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy.

Authors:  Liehua Liu; Xuesi Wan; Juan Liu; Zhimin Huang; Xiaopei Cao; Yanbing Li
Journal:  Diabetes Technol Ther       Date:  2012-06-25       Impact factor: 6.118

3.  Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention.

Authors:  Takayuki Fujiwara; Masashi Yoshida; Naoyuki Akashi; Hodaka Yamada; Takunori Tsukui; Tomohiro Nakamura; Kenichi Sakakura; Hiroshi Wada; Kenshiro Arao; Takuji Katayama; Tomio Umemoto; Hiroshi Funayama; Yoshitaka Sugawara; Takeshi Mitsuhashi; Masafumi Kakei; Shin-Ichi Momomura; Junya Ako
Journal:  Heart Vessels       Date:  2015-04-29       Impact factor: 2.037

4.  Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.

Authors:  Suk Chon; Yun Jung Lee; Gemma Fraterrigo; Paolo Pozzilli; Moon Chan Choi; Mi-Kwang Kwon; Sang Ouk Chin; Sang Youl Rhee; Seungjoon Oh; Young-Seol Kim; Jeong-Taek Woo
Journal:  Diabetes Technol Ther       Date:  2013-04-25       Impact factor: 6.118

5.  Dominant-negative mutant hepatocyte nuclear factor 1alpha induces diabetes in transgenic-cloned pigs.

Authors:  Kazuhiro Umeyama; Masahito Watanabe; Hitoshi Saito; Mayuko Kurome; Sadaaki Tohi; Hitomi Matsunari; Keizaburo Miki; Hiroshi Nagashima
Journal:  Transgenic Res       Date:  2009-04-09       Impact factor: 2.788

6.  Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk.

Authors:  Takayuki Fujiwara; Masashi Yoshida; Hodaka Yamada; Takunori Tsukui; Tomohiro Nakamura; Kenichi Sakakura; Hiroshi Wada; Kenshiro Arao; Takuji Katayama; Hiroshi Funayama; Yoshitaka Sugawara; Takeshi Mitsuhashi; Masafumi Kakei; Shin-Ichi Momomura; Junya Ako
Journal:  Heart Vessels       Date:  2014-04-02       Impact factor: 2.037

7.  Nontraditional markers of glycemia: associations with microvascular conditions.

Authors:  Elizabeth Selvin; Lesley M A Francis; Christie M Ballantyne; Ron C Hoogeveen; Josef Coresh; Frederick L Brancati; Michael W Steffes
Journal:  Diabetes Care       Date:  2011-02-18       Impact factor: 19.112

8.  Glycemic Profiles of Healthy Individuals with Low Fasting Plasma Glucose and HbA1c.

Authors:  Kyoko Nomura; Tomoyuki Saitoh; Gwang U Kim; Toshikazu Yamanouchi
Journal:  ISRN Endocrinol       Date:  2011-12-08

9.  Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.

Authors:  Aparna Pal; Andrew J Farmer; Christina Dudley; Mary P Selwood; Beryl A Barrow; Rhiannon Klyne; Jilly P Grew; Mark I McCarthy; Anna L Gloyn; Katharine R Owen
Journal:  Diabetes Care       Date:  2009-11-23       Impact factor: 19.112

10.  Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.

Authors:  Thomas Rauch; Ulrike Graefe-Mody; Carolyn F Deacon; Arne Ring; Jens J Holst; Hans-Juergen Woerle; Klaus A Dugi; Tim Heise
Journal:  Diabetes Ther       Date:  2012-09-18       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.